Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report

被引：0
|
作者：
Takahide Kimura
Seiki Yamada
Masayuki Tanemoto
机构：
[1] International University of Health and Welfare,Division of Nephrology, Department of Internal Medicine
来源：
SN Comprehensive Clinical Medicine | / 4卷 / 1期
关键词：
Chronic kidney disease; Gout; Hyperuricemia; Xanthine oxidase;
D O I：
10.1007/s42399-021-01081-1
中图分类号：
学科分类号：
摘要：
Hyperuricemia is a common complication of chronic kidney disease. Gout is a clinical symptom of hyperuricemia, and lowering serum uric acid concentration (sUA) is recommended to prevent its recurrence. Febuxostat and topiroxostat are sUA-lowering agents, which are presumed to act on the same site of xanthine oxidase (XO), the rate-limiting enzyme for urate production. We present a case of gout where febuxostat but not topiroxostat lowered sUA. The different efficacy between them indicates that XO inhibitors are not interchangeable even among those acting on the same site of XO.
引用
收藏
相关论文
共 50 条
  • [1] Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout
    Bruce, Susan P.
    [J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (12) : 2187 - 2194
  • [2] EFFECTS OF A XANTHINE OXIDASE INHIBITOR ON THIOPURINE METABOLISM, HYPERURICEMIA AND GOUT
    RUNDLES, RW
    WYNGAARDEN, JB
    HITCHINGS, GH
    ELION, GB
    SILBERMAN, HR
    [J]. TRANSACTIONS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, 1963, 76 : 126 - 140
  • [3] Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice
    Takahashi, Kazuhisa
    Mizukami, Hiroki
    Osonoi, Sho
    Ogasawara, Saori
    Hara, Yutaro
    Kudoh, Kazuhiro
    Takeuchi, Yuki
    Sasaki, Takanori
    Daimon, Makoto
    Yagihashi, Soroku
    [J]. NEUROBIOLOGY OF DISEASE, 2021, 155
  • [4] The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinolstudy protocol
    Sakuma, Masashi
    Toyoda, Shigeru
    Arikawa, Takuo
    Koyabu, Yota
    Kato, Toru
    Adachi, Taichi
    Suwa, Hideaki
    Narita, Jun-ichi
    Anraku, Koetsu
    Ishimura, Kimihiko
    Yamauchi, Fumitake
    Sato, Yasunori
    Inoue, Teruo
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (06) : 1379 - 1386
  • [5] PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA - USE OF ALLOPURINOL A XANTHINE OXIDASE INHIBITOR
    KRAKOFF, IH
    MEYER, RL
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 193 (01): : 1 - &
  • [6] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Matsuo, Hiroshi
    Ishikawa, Eiji
    Machida, Hirofumi
    Mizutani, Yasuhide
    Tanoue, Akiko
    Ohnishi, Takahiro
    Murata, Tomohiro
    Okamoto, Shinya
    Ogura, Toru
    Nishimura, Yuki
    Ito, Hiroo
    Yasutomi, Masashi
    Katayama, Kan
    Nomura, Shinsuke
    Ito, Masaaki
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (04) : 307 - 313
  • [7] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Hiroshi Matsuo
    Eiji Ishikawa
    Hirofumi Machida
    Yasuhide Mizutani
    Akiko Tanoue
    Takahiro Ohnishi
    Tomohiro Murata
    Shinya Okamoto
    Toru Ogura
    Yuki Nishimura
    Hiroo Ito
    Masashi Yasutomi
    Kan Katayama
    Shinsuke Nomura
    Masaaki Ito
    [J]. Clinical and Experimental Nephrology, 2020, 24 : 307 - 313
  • [8] HYPERURICEMIA IN NEOPLASTIC DISEASE IN CHILDREN - PREVENTION WITH ALLOPURINOL A XANTHINE OXIDASE INHIBITOR
    KRAKOFF, IH
    MURPHY, ML
    [J]. PEDIATRICS, 1968, 41 (1P1) : 52 - &
  • [9] TMX-67 -: Treatment of gout and hyperuricemia -: Xanthine oxidase inhibitor
    Sorbera, LA
    Revel, L
    Rabasseda, X
    Castañer, J
    [J]. DRUGS OF THE FUTURE, 2001, 26 (01) : 32 - 38
  • [10] The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol—study protocol
    Masashi Sakuma
    Shigeru Toyoda
    Takuo Arikawa
    Yota Koyabu
    Toru Kato
    Taichi Adachi
    Hideaki Suwa
    Jun-ichi Narita
    Koetsu Anraku
    Kimihiko Ishimura
    Fumitake Yamauchi
    Yasunori Sato
    Teruo Inoue
    [J]. Clinical and Experimental Nephrology, 2018, 22 : 1379 - 1386
12345